;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • F-star, F-star Beta deal

    F-star GmbH, Vienna, Austria F-star Beta Ltd., Cambridge, U.K. Business: Cancer F-star's F-star Biotechnology Ltd. subsidiary launched newco F-star Beta and granted it exclusive, worldwide rights to develop and …

    Published on 11/10/2014
  • Galecto, Bristol-Myers deal

    Galecto Biotech AB, Copenhagen, Denmark Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Pulmonary Galecto Biotech granted Bristol-Myers Squibb an exclusive option to acquire the biotech. Galecto's TD139, …

    Published on 11/10/2014
  • Genmab, J&J deal

    Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Genmab will receive a $10 million milestone payment from Johnson & Johnson's Janssen Biotech Inc. …

    Published on 11/10/2014
  • Hermes, PharmaEngine deal

    Hermes Biosciences Inc., South San Francisco, Calif. PharmaEngine Inc. (GreTai:4162), Taipei, Taiwan Business: Cancer Merrimack and PharmaEngine amended a 2011 deal under which PharmaEngine granted Merrimack exclusive, …

    Published on 11/10/2014
  • iBio, Novici Biotech deal

    iBio Inc. (NYSE-M:IBIO), Newark, Del. Novici Biotech LLC, Vacaville, Calif. Business: Pulmonary iBio and Novici expanded an exclusive commercialization deal focused on antibodies and vaccine products to include iBio's …

    Published on 11/10/2014
  • Incyte, Novartis deal

    Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Hematology Incyte will receive a $60 million milestone payment from Novartis under a 2009 deal granting the …

    Published on 11/10/2014
  • Intrexon, Histogenics deal

    Intrexon Corp. (NYSE:XON), Germantown, Md. Histogenics Corp., Waltham, Mass. Business: Gene/Cell therapy, Musculoskeletal Intrexon granted Histogenics access to technologies to develop allogeneic genetically modified …

    Published on 11/10/2014
  • IRCM, Liphorus Pharmaceuticals deal

    Institut de Recherches Cliniques de Montreal (IRCM), Montreal, Quebec Liphorus Pharmaceuticals Inc., Montreal, Quebec Business: Endocrine/Metabolic IRCM spun out Liphorus and granted the newco exclusive, worldwide …

    Published on 11/10/2014
  • Iroko, Aspen deal

    Iroko Pharmaceuticals LLC, Philadelphia, Pa. Aspen Pharmacare Holdings Ltd. (JSE:APN), Durban, South Africa Business: Neurology Iroko's Iroko Pharmaceuticals Inc. affiliate granted Aspen's Aspen Pharmacare Australia Pty…

    Published on 11/10/2014
  • Iroko, Landsteiner deal

    Iroko Pharmaceuticals LLC, Philadelphia, Pa. Landsteiner Scientific S.A. de C.V., Mexico City, Mexico Business: Neurology Iroko's Iroko Pharmaceuticals Inc. affiliate granted Landsteiner exclusive rights to develop and …

    Published on 11/10/2014
  • Lead Discovery Center, German Cancer Research Center deal

    Lead Discovery Center GmbH, Dortmund, Germany German Cancer Research Center, Heidelberg, Germany Business: Cancer The Lead Discovery Center launched an initial pilot project with a research group in the German Cancer …

    Published on 11/10/2014
  • Marinomed, Nicox deal

    Marinomed Biotechnologie GmbH, Vienna, Austria Nicox S.A. (Euronext:COX), Sophia Antipolis, France Business: Infectious Nicox acquired Marinomed's Carragelose antiviral eye drop program for EUR2.7 million ($3.3 million)…

    Published on 11/10/2014
  • Novartis, Tribute Pharmaceuticals deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF;TSX-V:TRX), Milton, Ontario Business: Neurology, Cardiovascular Novartis sold to Tribute Canadian rights to Fiorinal …

    Published on 11/10/2014
  • Proteostasis, Astellas deal

    Proteostasis Therapeutics Inc., Cambridge, Mass. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Pharmaceuticals, Proteomics Astellas and Proteostasis partnered to use Proteostasis' technologies to discover …

    Published on 11/10/2014
  • pSivida, Alimera Sciences deal

    pSivida Corp. (NASDAQ:PSDV;ASX:PVA), Watertown, Mass. Alimera Sciences Inc. (NASDAQ:ALIM), Alpharetta, Ga. Business: Ophthalmic pSivida received a $25 million milestone payment under a 2008 deal granting Alimera full …

    Published on 11/10/2014
  • Ridge Diagnostics, AIT Laboratories deal

    Ridge Diagnostics Inc., San Diego, Calif. AIT Laboratories, Indianapolis, Ind. Business: Diagnostic AIT received exclusive distribution rights in the U.S. to MDDScore depression blood test from Ridge for pain management…

    Published on 11/10/2014
  • Salix, Lupin deal

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Lupin Ltd. (NSE:LUPIN;BSE:500257), Mumbai, India Business: Hepatic, Gastrointestinal Salix granted Lupin exclusive rights to market Zaxine rifaximin 550 mg and …

    Published on 11/10/2014
  • SomaLogic, Novartis deal

    SomaLogic Inc., Boulder, Colo. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Proteomics Novartis' Novartis Institutes for BioMedical Research (NIBR) and SomaLogic extended a partnership for two …

    Published on 11/10/2014
  • Transcept, Paratek deal

    Transcept Pharmaceuticals Inc., Point Richmond, Calif. Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), Boston, Mass. Business: Neurology, Infectious Transcept completed its reverse merger with Paratek (see BioCentury, July …

    Published on 11/10/2014
  • XL-protein, Weizmann Institute of Science deal

    XL-protein GmbH, Freising, Germany Weizmann Institute of Science, Rehovot, Israel Business: Autoimmune, Inflammation XL-protein granted Weizmann Institute's Yeda Research and Development Co. Ltd. technology transfer …

    Published on 11/10/2014
  • AKTivate Therapeutics, Virax deal

    AKTivate Therapeutics Pty. Ltd., Brisbane, Australia Virax Holdings Ltd. (ASX:VHL), Melbourne, Australia Business: Cancer Virax will acquire AKTivate Therapeutics for $300,000 in cash and 134 million shares up front …

    Published on 11/3/2014
  • Cardiorentis, Roche deal

    Cardiorentis AG, Zug, Switzerland Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cardiovascular Cardiorentis will incorporate undisclosed in vitro diagnostics from Roche in the ongoing Phase III TRUE-AHF …

    Published on 11/3/2014
  • F-star Alpha, Bristol-Myers deal

    F-star Alpha Ltd., Cambridge, U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Bristol-Myers Squibb received an exclusive option to acquire F-star Alpha and gain worldwide rights to FS102, a …

    Published on 11/3/2014
  • Foundation Medicine, WuXi PharmaTech deal

    Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. WuXi PharmaTech Inc. (NYSE:WX), Shanghai, China Business: Diagnostic Foundation Medicine will grant WuXi non-exclusive rights to offer Foundation Medicine's …

    Published on 11/3/2014
  • General Electric, GlaxoSmithKline deal

    General Electric Co. (NYSE:GE), Fairfield, Conn. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Cancer General Electric's Clarient Diagnostic Services Inc. company and GlaxoSmithKline partnered to form a…

    Published on 11/3/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993